Author: Wijtvliet, V. P. W. M.; Arien, K. K.; Abrams, S.; Couttenye, M. M.; Mestrez, F.; Marien, J.; De Winter, B. Y.; Van Damme, P.; Pipeleers, L.; Wissing, K. M.; Abramowicz, D.; Ledeganck, K.
Title: mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients? Cord-id: o741c2yf Document date: 2021_9_22
ID: o741c2yf
Snippet: In this study of the humoral immune response after the first dose of SARS-CoV-2 mRNA vaccine, low seroconversion rates were noted in both kidney transplant recipients and dialysis patients. However, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean antibody titers compared to BNT162b2 (Pfizer).
Document: In this study of the humoral immune response after the first dose of SARS-CoV-2 mRNA vaccine, low seroconversion rates were noted in both kidney transplant recipients and dialysis patients. However, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean antibody titers compared to BNT162b2 (Pfizer).
Search related documents:
Co phrase search for related documents- logistic regression and low seroconversion rate: 1, 2
Co phrase search for related documents, hyperlinks ordered by date